Scotland says no to Daiichi Sankyo’s cholesterol drug NilemdoThe Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, Share XScotland says no to Daiichi Sankyo’s cholesterol drug Nilemdohttps://pharmaphorum.com/news/scotland-says-no-to-daiichi-sankyos-cholesterol-drug-nilemdo/
AstraZeneca sells rights to cholesterol drug Crestor to GrunenthalAstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a Share XAstraZeneca sells rights to cholesterol drug Crestor to Grunenthalhttps://pharmaphorum.com/news/astrazeneca-sells-rights-to-cholesterol-drug-crestor-to-grunenthal/
Novartis’ big bet on inclisiran nears fruition, as CHMP backs drugNovartis’ near-$10 billion takeover of The Medicines Company last year was focused mainly on one asset – cholesterol-lowering Share XNovartis’ big bet on inclisiran nears fruition, as CHMP backs drughttps://pharmaphorum.com/news/novartis-big-bet-on-inclisiran-nears-fruition-as-chmp-backs-drug/
AZ buys oral PCSK9 cholesterol drug from Dogma TherapeuticsAstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering Share XAZ buys oral PCSK9 cholesterol drug from Dogma Therapeuticshttps://pharmaphorum.com/news/az-buys-oral-pcsk9-cholesterol-drug-from-dogma-therapeutics/
Novartis strikes landmark deal with NHS to speed up inclisiran accessNovartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran Share XNovartis strikes landmark deal with NHS to speed up inclisiran accesshttps://pharmaphorum.com/news/novartis-strikes-landmark-deal-with-nhs-to-speed-up-inclisiran-access/
Amgen pulls higher-priced Repatha to try to lift salesMore than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t Share XAmgen pulls higher-priced Repatha to try to lift saleshttps://pharmaphorum.com/news/amgen-pulls-higher-priced-repatha-to-try-to-lift-sales/
TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering Share XTMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/
TMC inches closer to inclisiran approval with long-term safety dataThe Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety Share XTMC inches closer to inclisiran approval with long-term safety datahttps://pharmaphorum.com/news/tmc-inches-closer-to-inclisiran-approval-with-long-term-safety-data/
Merck axes cholesterol drug despite phase 3 successMerck & Co has said it will not file anacetrapib with regulators Share XMerck axes cholesterol drug despite phase 3 successhttps://pharmaphorum.com/news/merck-axes-cholesterol-drug-despite-phase-3-success/